Found: 45
Select item for more details and to access through your institution.
The Utility of 24-h Ambulatory Blood Pressure Monitoring for the Diagnosis and Management of White Coat Hypertension in a Primary Care Setting.
- Published in:
- Journal of Primary Care & Community Health, 2022, v. 13, p. 1, doi. 10.1177/21501319221123457
- By:
- Publication type:
- Article
Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.
- Published in:
- Clinical Hypertension, 2022, v. 28, n. 1, p. 1, doi. 10.1186/s40885-022-00197-3
- By:
- Publication type:
- Article
The Utility of 24-h Ambulatory Blood Pressure Monitoring for the Diagnosis and Management of White Coat Hypertension in a Primary Care Setting.
- Published in:
- Journal of Primary Care & Community Health, 2022, v. 13, p. 1, doi. 10.1177/21501319221123457
- By:
- Publication type:
- Article
Emerging therapeutic agents for genitourinary cancers.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13045-019-0780-z
- By:
- Publication type:
- Article
Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis.
- Published in:
- Clinical Hypertension, 2019, v. 25, n. 1, p. N.PAG, doi. 10.1186/s40885-019-0110-3
- By:
- Publication type:
- Article
Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis.
- Published in:
- Clinical Hypertension, 2019, v. 25, n. 1, p. N.PAG, doi. 10.1186/s40885-019-0110-3
- By:
- Publication type:
- Article
Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.
- Published in:
- Current Oncology Reports, 2018, v. 20, n. 5, p. 1, doi. 10.1007/s11912-018-0684-z
- By:
- Publication type:
- Article
Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
- Published in:
- Oncology, 2018, v. 94, n. 5, p. 259, doi. 10.1159/000486679
- By:
- Publication type:
- Article
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.
- Published in:
- Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-016-0374-y
- By:
- Publication type:
- Article
Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.
- Published in:
- Acta Oncologica, 2016, v. 55, n. 9/10, p. 1196, doi. 10.3109/0284186X.2016.1168939
- By:
- Publication type:
- Article
Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma.
- Published in:
- Biomarker Research, 2015, v. 3, n. 1, p. 1, doi. 10.1186/s40364-015-0030-7
- By:
- Publication type:
- Article
Incidence and risk of rash to mTOR inhibitors in cancer patients - a meta-analysis of randomized controlled trials.
- Published in:
- Acta Oncologica, 2015, v. 54, n. 1, p. 124, doi. 10.3109/0284186X.2014.923583
- By:
- Publication type:
- Article
Alopecia With Endocrine Therapies in Patients With Cancer.
- Published in:
- Oncologist, 2013, v. 18, n. 10, p. 1126, doi. 10.1634/theoncologist.2013-0193
- By:
- Publication type:
- Article
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
- Published in:
- Acta Oncologica, 2013, v. 52, n. 6, p. 1202, doi. 10.3109/0284186X.2013.782103
- By:
- Publication type:
- Article
Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 4, p. 424, doi. 10.1016/j.clml.2013.03.006
- By:
- Publication type:
- Article
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 1078, doi. 10.1007/s10637-013-9977-0
- By:
- Publication type:
- Article
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 787, doi. 10.1007/s10637-013-9927-x
- By:
- Publication type:
- Article
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
- Published in:
- Dermatologic Therapy, 2013, v. 26, n. 2, p. 135, doi. 10.1111/dth.12027
- By:
- Publication type:
- Article
Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.
- Published in:
- European Journal of Haematology, 2013, v. 90, n. 2, p. 142, doi. 10.1111/ejh.12052
- By:
- Publication type:
- Article
The efficacy of temozolomide for recurrent glioblastoma multiforme.
- Published in:
- European Journal of Neurology, 2013, v. 20, n. 2, p. 223, doi. 10.1111/j.1468-1331.2012.03778.x
- By:
- Publication type:
- Article
Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 135, n. 2, p. 347, doi. 10.1007/s10549-012-2157-7
- By:
- Publication type:
- Article
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1773, doi. 10.1007/s10637-011-9652-2
- By:
- Publication type:
- Article
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
- Published in:
- Acta Oncologica, 2011, v. 50, n. 7, p. 997, doi. 10.3109/0284186X.2011.581689
- By:
- Publication type:
- Article
Inverse association between eczema and meningioma: a meta-analysis.
- Published in:
- Cancer Causes & Control, 2011, v. 22, n. 10, p. 1355, doi. 10.1007/s10552-011-9808-6
- By:
- Publication type:
- Article
Bevacizumab and Cancer Treatment-Related Mortality.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities.
- Published in:
- Oncologist, 2011, v. 16, n. 5, p. 543, doi. 10.1634/theoncologist.2010-0263
- By:
- Publication type:
- Article
Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis.
- Published in:
- JAMA: Journal of the American Medical Association, 2011, v. 305, n. 5, p. 487, doi. 10.1001/jama.2011.51
- By:
- Publication type:
- Article
Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis.
- Published in:
- Oncology, 2010, v. 79, n. 1/2, p. 27, doi. 10.1159/000314980
- By:
- Publication type:
- Article
Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis.
- Published in:
- American Journal of Hypertension, 2010, v. 23, n. 5, p. 460, doi. 10.1038/ajh.2010.25
- By:
- Publication type:
- Article
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials.
- Published in:
- Acta Oncologica, 2010, v. 49, n. 3, p. 287, doi. 10.3109/02841860903524396
- By:
- Publication type:
- Article
Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis.
- Published in:
- Oncology, 2009, v. 77, n. 2, p. 124, doi. 10.1159/000229752
- By:
- Publication type:
- Article
Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Increased Risk of High-Grade Dermatologic Toxicities With Radiation Plus Epidermal Growth Factor Receptor Inhibitor Therapy.
- Published in:
- Cancer (0008543X), 2009, v. 115, n. 6, p. 1286, doi. 10.1002/cncr.24120
- By:
- Publication type:
- Article
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis.
- Published in:
- Acta Oncologica, 2009, v. 48, n. 1, p. 9, doi. 10.1080/02841860802314720
- By:
- Publication type:
- Article
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 300, n. 19, p. 2277, doi. 10.1001/jama.2008.656
- By:
- Publication type:
- Article
Evolving Strategies for the Management of Hand--Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib.
- Published in:
- Oncologist, 2008, v. 13, n. 9, p. 1001, doi. 10.1634/theoncologist.2008-0131
- By:
- Publication type:
- Article
Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis.
- Published in:
- Acta Oncologica, 2008, v. 47, n. 2, p. 176, doi. 10.1080/02841860701765675
- By:
- Publication type:
- Article
The use of bisphosphonates in cancer patients.
- Published in:
- Acta Oncologica, 2007, v. 46, n. 5, p. 581, doi. 10.1080/02841860701233435
- By:
- Publication type:
- Article
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
- Published in:
- BJU International, 2007, v. 99, n. 5, p. 1047, doi. 10.1111/j.1464-410X.2007.06763.x
- By:
- Publication type:
- Article
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
- Published in:
- BJU International, 2007, v. 99, n. 3, p. 525, doi. 10.1111/j.1464-410X.2006.06654.x
- By:
- Publication type:
- Article
Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange.
- Published in:
- Immunological Reviews, 1999, v. 172, n. 1, p. 239, doi. 10.1111/j.1600-065X.1999.tb01369.x
- By:
- Publication type:
- Article
Polymorphism at β85 and not β86 of HLA-DR1 is predominantly responsible for restricting the nature of the anchor side chain: implication for concerted effects of class II MHC polymorphism.
- Published in:
- International Immunology, 1997, v. 9, n. 10, p. 1495
- By:
- Publication type:
- Article